UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041139
Receipt number R000046065
Scientific Title Prospective, randomized, open-label, clinical trial comparing the effects of pemafibrate and ethyl icosapentate on glucose/lipids metabolism and endothelial function in patients with hyperlipidemia
Date of disclosure of the study information 2020/08/01
Last modified on 2022/10/21 11:42:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective, randomized, open-label, clinical trial comparing the effects of pemafibrate and ethyl icosapentate on glucose/lipids metabolism and endothelial function in patients with hyperlipidemia

Acronym

Effects of pemafibrate and ethyl icosapentate on endothelial function

Scientific Title

Prospective, randomized, open-label, clinical trial comparing the effects of pemafibrate and ethyl icosapentate on glucose/lipids metabolism and endothelial function in patients with hyperlipidemia

Scientific Title:Acronym

Effects of pemafibrate and ethyl icosapentate on endothelial function

Region

Japan


Condition

Condition

Hyperlipidemia

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of pemafibrate versus ethyl icosapentate on glucose/lipids metabolism and endothelial function in patients with hyperlipidemia

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Flow-mediated vasodilation in forearm
Six weeks after administration

Key secondary outcomes

Hemoglobin A1C levels, glycoalbumin levels, fasting blood glucose, lipids levels, HDL function, markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria/L-FABP)
Six weeks after administration


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of pemafibrate first, then change to ethyl icosapentate

Interventions/Control_2

Administration of ethyl icosapentate first, then change to pemafibrate

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Hypertriglycemia patients whose fasting blood triglyceride levels greater than 150mg/dl.
2) Outpatients
3) Subjects who gave written informed consent

Key exclusion criteria

1) Allergy against pemafibrate/ethyl icosapentate
2) Poor-controlled diabetes (HbA1c>10.0 %)
3) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
4) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits
5) End stage renal failure
6) Symptomatic (NYHA III or IV) congestive heart failure
7) Malignancies or other diseases with poor prognosis
8) Pregnant
9) Subjects whose doctor in charge do not agree to join the trial

Target sample size

33


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Sasaki

Organization

National Defense Medical College

Division name

Division of Anti-aging and Vascular Medicine, Department of Internal Medicine,

Zip code

359-8513

Address

3-2 Namiki, Tokorozawa, Japan

TEL

0429951211

Email

con301@ndmc.ac.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Sasaki

Organization

National Defense Medical College

Division name

Division of Anti-aging and Vascular Medicine, Department of Internal Medicine,

Zip code

359-8513

Address

3-2 Namiki, Tokorozawa, Japan

TEL

0429951211

Homepage URL


Email

con301@ndmc.ac.jp


Sponsor or person

Institute

National Defense Medical College

Institute

Department

Personal name



Funding Source

Organization

Foundation for Promotion of Defense Medicine

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Defense Medical College IRB

Address

3-2 Namiki, Tokorozawa, Japan

Tel

04-2995-1211

Email

rinri@ndmc.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 01 Month 01 Day

Date of IRB

2019 Year 12 Month 24 Day

Anticipated trial start date

2020 Year 01 Month 15 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 07 Month 17 Day

Last modified on

2022 Year 10 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046065


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name